Quote this publication Share Print

VENTAVIS

-
Opinions on drugs - Posted on Jan 05 2011

Reason for request

Reassessment of actual benefit and improvement in actual benefit (AB) under article R-163-21 of the Social Security Code.

-


Clinical Benefit

Moderate

The actual benefit is moderate.


Clinical Added Value

minor

The Transparency Committee considers that the proprietary drug VENTAVIS provides a minor improvement in actual benefit (IAB IV) in the treatment of idiopathic pulmonary arterial hypertension for patients in functional class III.


Contact Us

Évaluation des médicaments

See also